|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure显示文摘Hepatitis B virus(HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma(HCC). During the last two decades, with the use of currently available anti-HBV therapies(lamivudine, entecavir and tenofovir disoproxil fumatate), there has been a decrease in the incidence of HBVassociated HCC(HBV-HCC). Furthermore, several studies have demonstrated a reduction in recurrent or new HCC development after initial HCC tumor ablation. However, during an observation period spanning 10 to 20 years, several case reports have demonstrated the development of new, subsequent new and recurrent HCC even in patients with undetectable serum HBV DNA. The persistent risk for HCC is attributed to the presence of covalently closed circular DNA(cccDNA) in the hepatocyte nucleus which continues to work as a template for HBV replication. While a functional cure(loss of hepatitis B surface antigen and undetectable viral DNA) can be attained with nucleos(t)ide analogues, these therapies do not eliminate cccDNA. Of utmost importance is successful eradication of the transcriptionally active HBV cccDNA from hepatocyte nuclei which would be considered a complete cure. The unpredictable nature of HCC development in patients with chronic HBV infection shows the need for a complete cure. Continued support and encouragement for research efforts aimed at developing curative therapies is imperative. The aims of this minireview are to highlight these observations and emphasize the need for a cure for HBV. | Brianna J Shinn Aaron Martin Robert M Coben Mitchell I Conn Jorge Prieto Howard Kroop Anthony J DiMarino Hie-Won Hann | 2019 | World Journal of Hepatology2019，11，1： | 3 |
| 2 | The Impact on UK Acquires of Do- mestic, Cross-border, Public and Private Acquisitions显示文摘 | Robert Conn Paul Mgh Guest | 2005 | Joumal of Business Finance and Accounting2005，，： | 1 |
| 3 | A trisomic germ cell line and precocious chromatid segregation leads to recurrent trisomy 21 conception显示文摘 | J. Cozzi Clare M. Conn Joyce Harper Robert M. L. Winston M. Rindl Peter A. Farndon J. D. A. Delhanty | 1999 | Human Genetics1999，，1： | 1 |
| 4 | Infertile couples with Robertsonian translocations: preimplantation genetic analysis of embryos reveals chaotic cleavage divisions显示文摘 | C. M. Conn Joyce C. Harper Robert M. L. Winston Joy D. A. Delhanty | 1998 | Human Genetics1998，，1： | 1 |
| 5 | Beryllium as the plasma-facing material in fusion energy systems-experiments, evaluation, and comparison with alternative materials 显示文摘 | Robert W Conn Russell P Doerner Jongik Won | 1997 | Fusion Engineering and Design1997，37，： | 1 |
| 6 | Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process显示文摘Red blood cells(RBCs)can act as carriers for therapeutic agents and can substantially improve the safety,pharmacokinetics,and pharmacodynamics of many drugs.Maintaining RBCs integrity and lifespan is important for the efficacy of RBCs as drug carrier.We investigated the impact of drug encapsulation by hypotonic dialysis on RBCs physiology and integrity.Several parameters were compared between processed RBCs loaded with l-asparaginase(“eryaspase”),processed RBCs without drug and non-processed RBCs.Processed RBCs were less hydrated and displayed a reduction of intracellular content.We observed a change in the metabolomic but not in the proteomic profile of processed RBCs.Encapsulation process caused moderate morphological changes and was accompanied by an increase of RBCs-derived Extracellular Vesicles release.Despite a decrease in deformability,processed RBCs were not mechanically retained in a spleen-mimicking device and had increased surface-to-volume ratio and osmotic resistance.Processed RBCs half-life was not significantly affected in a mouse model and our previous phase 1 clinical study showed that encapsulation of asparaginase in RBCs prolonged its in vivo half-life compared to free forms.Our study demonstrated that encapsulation by hypotonic dialysis may affect certain characteristics of RBCs but does not significantly affect the in vivo longevity of RBCs or their drug carrier function. | Mélanie Robert Bastien Laperrousaz Diana Piedrahita Emilie-Fleur Gautier Travis Nemkov Florian Dupuy Elie Nader Virginie Salnot Patrick Mayeux Angelo D’Alessandro Catherine Lavazec Philippe Joly Alexander Scheer Philippe Connes Agnès Cibiel | 2022 | Acta Pharmaceutica Sinica B2022，12，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员